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ABSTRACT 
In Pennsylvania, rural and urban communities can differ in the various factors that impact 
healthcare outcomes. The social ecological model was used as a lens to view underlying factors in 
the literature related to the opioid epidemic that affect an individual’s susceptibility to opioid use 
disorder in rural and urban populations. The Substance Abuse and Mental Health Services 
Administration treatment provider search function was used to examine rates of buprenorphine, 
drug and alcohol and mental health, and detoxification providers across the Commonwealth of 
Pennsylvania. Following the literature review and provider search, several factors were viewed to 
affect rural populations moreso than urban populations: the occupation of an individual, social 
networks, recovery support services, and access to buprenorphine and detoxification providers. 
Several factors were also found to be similar between urban and rural populations: individual risk 
factors, perceived norms towards substance use disorder, family, peer influence, stigma, 
socioeconomic status, rates of drug and alcohol and mental health treatment providers, and policies 
related to substance use disorder.  
All these factors also have the ability to intermix and impact outcomes, such as perceived 
norms and stigma, which can combine to create low levels of access to treatment and recovery 
services. Several strategies could be used to overcome these barriers to care in rural populations. 
Behavioral health can be integrated into primary care offices. Telemedicine can be fully optimized 
ACCOUNTING FOR RURAL VERSUS URBAN DIFFERENCES IN THE OPIOID 
EPIDEMIC IN PENNSYLVANIA 
 
John Warwick, MPH 
University of Pittsburgh, 2018 
Martha A. Terry, PhD  
 v 
to increase access to specialty services in rural communities. Finally, Medicaid policies can be 
adapted to make these strategies more achievable for providers of rural healthcare clinics. By 
incentivizing and increasing reimbursement for medication-assisted treatment and opioid use 
disorder management and prevention, Medicaid beneficiaries can have increased access to 
treatment necessary for recovery. In the future, public health policies and interventions that take 
both the differences and similarities of rural and urban communities into account, can have greater 
success in overdose reduction and decreasing rates of opioid use disorder across Pennsylvania and 
the United States.  
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1.0  INTRODUCTION 
The current opioid epidemic in the United States, defined by the rapid increase in opioid use among 
the population, began over 20 years ago partially as a result of the increase in prescription opioid 
use.1 In the late 1990s, state medical boards reduced restrictions for prescribing opioids for chronic 
non-cancer pain. In 2000, the Joint Commission on the Accreditation of Healthcare Organizations 
introduced new pain management standards that brought increased awareness to the “right to be 
pain-free.” Additionally, aggressive marketing by pharmaceutical companies and the promotion 
of opioids over other methods of pain therapy are also associated with increased opioid use.1   
 These factors have contributed to the increase in the number of prescription opioids in the 
United States, which contributes to the non-medical use of prescription opioids.2 The nonmedical 
use of prescription opioids varies throughout the population from relatively infrequent use once or 
twice a year to daily use and corresponding addiction.3 In 2014, a total of 10.3 million people 
reported using opioids in a manner other than prescribed or using opioid medications that were not 
originally prescribed for them.4 One population, people who use heroin, are 3.9 times more likely 
to report using prescription opioids nonmedically.5 
In addition to nonmedical prescription opioid use, heroin use has increased in the United 
States over the past decade, especially since 2007.6  Between 2002 and 2004, heroin use for 
nonmedical prescription opioid users increased 138.9%.4 Heroin users have also reported increased 
use of and dependence on cocaine, alcohol, and marijuana.3,6 The rate of use has increased in young 
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adults aged 18 to 25, in urban and rural areas, and among all sexes, races, and ethnic groups. Heroin 
use rates have increased the most among non-Hispanic whites and women.3,6 Heroin users entering 
treatment are predominantly white, middle-class, and living in non-urban areas of the country. 
These patterns associated with heroin use are similar to those of nonmedical prescription opioid 
use since 2002.3,4,7-9  
Misuse of prescription and non-prescription opioids has several consequences. First, 
increased misuse of opioids has been associated with increased drug overdose rates. Drug 
overdoses have become the leading cause of death for Americans younger than 50 years of age.10 
Second, opioid misuse and dependence are associated with increased readmission rates following 
major operating room surgery.11 Third, increased opioid use has been associated with increased 
healthcare costs. The total economic burden of prescription opioid misuse has been estimated at 
$78 billion.12 Substance use disorder (SUD) costs the United States an estimated $442 billion a 
year.13 This includes the costs of healthcare, lost productivity, treatment, and the involvement of 
the criminal justice system.13,14 These consequences combine to have a large effect on the economy 
and health of the entire population of the United States.   
Recently, state and federal levels of government have taken action to reduce opioid 
overdose deaths. The United States government has enacted policies to mitigate inappropriate 
opioid prescribing.2 Policies include implementing prescription drug monitoring programs 
(PDMPs), taking legal action against physicians and pharmacists aberrantly prescribing or 
dispensing opioid medications, initiating drug disposal programs, and building coalitions across 
the country to bring key stakeholders together to share success and develop community action 
plans.3,15 
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Addressing the issues behind the opioid epidemic requires a comprehensive set of 
initiatives related to public health policy and prevention in the medical and public health 
community. Improving access to, as well as methods of treatment, targeting the major risks factors, 
managing the availability of opioids to the public, and properly addressing differences in the 
populations of the United States when creating new programs and policies, will assist in the fight 
against fatal opioid overdose.3,16  
Pennsylvania ranks fourth in the country in opioid deaths at 37.9 per 100,000 (age-
adjusted).17 In 2016, 4,642 drug overdose deaths occurred in Pennsylvania.18 In January of 2018, 
Governor Tom Wolf declared the opioid epidemic a statewide disaster emergency, the first of its 
kind in Pennsylvania. This declaration aims to enhance state response and increase access to 
treatment by promoting collaborative initiatives between all state agencies.19 This will allow more 
people to receive necessary treatments and increase their chances for optimal health outcomes.  
1.1 PURPOSE 
The purpose of this thesis is to examine variations in the use of opioid-related mortality rates, 
access to treatment options and providers, and risk factors for opioid use disorder (OUD) and SUD 
in Pennsylvania. It will examine differences and similarities in the opioid epidemic between rural 
and urban populations at the policy, organizational, community, interpersonal, and individual 
levels as outlined in the Social Ecological Model (SEM). This thesis will also discuss where access 
to treatment services needs to be enhanced and suggest policy changes to better address those 
needs.  
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1.2 OBJECTIVES 
This thesis has five main objectives. The first is to provide a background on the opioid epidemic. 
The reader will review the neuroscience of opioids and how opioid use can lead to dependence. 
This thesis will also review epidemiological data related to the opioid epidemic and drug overdose 
in the Commonwealth of Pennsylvania and how the Commonwealth relates to the rest of the United 
States. Second, this paper will provide information on the types of treatment available for opioid 
use disorder (OUD) and the rates of treatment providers in rural and urban counties in 
Pennsylvania. Third, it will demonstrate the differences in rural and urban populations using the 
SEM to guide a literature review. Fourth, this paper will use the Substance Abuse and Mental 
Health Services (SAMHSA) provider search tool to locate SUD treatment providers in each county 
of Pennsylvania. Finally, policy suggestions will be provided based on the results of the literature 
review to better address opioid overdose and associated co-morbidities in rural and urban 
populations. Through these five main objectives, this thesis will provide reasonable strategies to 
prevent future deaths from drug-related overdose.  
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2.0  BACKGROUND 
This section will provide a background on the neuroscience of opioids, OUD, opioid overdose, 
and relevant statistics and epidemiological findings. It will then review various treatment methods 
for OUD. Next, it will provide background on rural and urban methods of classification for 
populations. Finally, it will review data related to access to various types of care for OUD in rural 
and urban counties throughout Pennsylvania.  
2.1 EXAMINING THE OPIOID EPIDEMIC 
The first section will discuss how opioids impact the human body. Next, it will discuss how high 
quantities of opioids can lead to overdose. It will then review the definition of OUD and provide 
background on the epidemiological impact of the opioid epidemic on Pennsylvania compared to 
the rest of the United States.  
2.1.1 NEUROSCIENCE OF OPIOIDS  
In order to understand why treating OUD is so difficult, it is important to understand how opioids 
affect the brain and become addictive. The term “opioid” refers to any natural, synthetic, or semi-
synthetic agent that has the functional and pharmacological properties of an opiate. “Opiate” refers 
to compounds that are structurally related to naturally occurring products found in the opium 
poppy.20 The different classes of opioid ligands act on three classes of opioid receptors: mu, kappa, 
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and delta.21,22 These G-protein-coupled receptors are widely distributed throughout the central 
nervous system and are expressed in a variety of peripheral tissues, such as vascular, cardiac, lung, 
gastro-intestinal system, and resident and circulating inflammatory cells.23 Each of the three kinds 
of opioid receptors is activated throughout the body when the opioid enters the blood stream and 
binds to the receptors of the central nervous system.  
Opioids’ interaction with the central nervous system is what gives them their addictive 
properties. Opioids weaken pain signals, and create euphoria and relaxation, which is why they are 
effective for treating pain.24 However, opioids also change the chemical structure of the brain. 
Opioids cause the release of dopamine, which can motivate patients to pursue behaviors that cause 
dopamine to be released, such as eating, having sexual intercourse, or taking a pill.25 Additionally, 
opioids mitigate the release of endorphins, the body’s natural pain relief neurotransmitters. Thus, 
when the brain runs out of opioids to react to, there are no endorphins to fill the opioid’s place – 
dopamine levels drop, and pain and uncomfortable symptoms return, often at stronger intensities. 
Therefore, people often experience rapid tolerance to opioids, and as a result, need to consume 
more opioids to relieve the pain and symptoms.25,26 When an individual reaches a level where the 
pain and withdrawal symptoms are so uncomfortable that he or she cannot function without 
opioids, or are at risk of death, the individual becomes dependent on the drug.26  
2.1.2 OPIOID OVERDOSE 
A fatal or non-fatal overdose from opioids occurs when there is an over-accumulation of opioids 
in the body, which can lead to respiratory depression, general unconsciousness, and death. When 
used in combination with alcohol and sedative medications, such as benzodiazepines, the risk of 
respiratory depression and death increases.27 In 2016, 145 Americans died each day on average 
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from an opioid-related drug overdose.28 Fatal opioid overdose occurs in all sex, ethnic, and age, 
populations and geographic locations.29  
The ability of opioids to create euphoria and relieve pain in various patient populations has 
led to the creation of many different synthetic and semi-synthetic agents. Synthetic opioids, such 
as fentanyl, are commonly used to cut street heroin to increase its effect due to low production 
costs.30 This increase in potency can be dangerous for unsuspecting people who use drugs.31 The 
increase in opioid overdose in the United States is largely a result of the rise and development of 
synthetic opioids following 2013.32,33 The increase in the use of fentanyl in street heroin has made 
it easier to overdose. People who use drugs often believe that they are administering the same 
quantity of drug into their body. They are not aware that when heroin is cut with fentanyl, the dose 
they normally administer is ten to one thousand times as powerful.34 However, people who use 
drugs and have a tolerance to opioids, often also seek synthetic opioids, like fentanyl, due to their 
strength and correspondingly powerful high.35  
2.1.3 OPIOID USE DISORDER 
OUD is defined as “a problematic pattern of opioid use leading to clinically significant impairment 
or distress.”36 This form of SUD is characterized by a persistent desire for opioids, an inability to 
control or reduce the use of opioids, continued use despite inability to fulfill major life or social 
obligations, chronic use at high dosages over long periods of time, development of tolerance, 
spending a large amount of time searching for opioids to use, and appearance of withdrawal 
symptoms following reduction or stopping of use. Common withdrawal symptoms include 
depression, nausea or vomiting, muscle aching, diarrhea, fever, and insomnia.36  
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2.1.4 EPIDEMOLIGCAL FINDINGS RELATED TO OPIOID OVERDOSE  
The opioid epidemic has impacted the entire United States. The rate of death due to opioid-related 
overdose has increased by more than 200% over the past 15 years throughout the country. Opioids 
were involved in 42,249 deaths in 2016. According to national health statistics data, in 2016 the 
five states with the highest rates of death due to drug overdose were West Virginia (52.0 per 
100,000), Ohio (39.1 per 100,000), New Hampshire (39.0 per 100,000), Pennsylvania (37.9 per 
100,000), and Kentucky (33.5 per 100,000).17 
In Pennsylvania in 2016, out of the 4,642 drug overdose deaths, 1,074 (23%) were  
individuals who lived in 48 counties listed as “rural” and 3,568 (77%) were in counties listed as 
“urban” using the Center for Rural Pennsylvania’s definitions. 18 Figures 1 and 2 below display 
the drug overdose death rates for urban and rural counties, respectively. The urban and rural 
counties with the highest overdose death rates in 2016 were Philadelphia and Beaver (urban) and 
Cambria and Fulton (rural). According to the 2016 Drug Enforcement Agency Report, the 
Pennsylvania drug-related overdose death rate in 2016 was 36.5 per 100,000 people, up from 26.7 
per 100,000 people in 2015, an increase of 37%.18 This is in comparison to the national drug 
overdose death rate in 2015 of 16.3 per 100,000. Seventy-eight percent of Pennsylvania counties 
experienced overdose death rates higher than the national average.17,18 
 9 
 
Figure 1: 2016 Overdose Death Rates for Urban Pennsylvania Counties (Gray Bar Equals Average Death Rate of 
Urban Pennsylvania Counties)  
 
Figure 2: 2016 Overdose Death Rates for Rural Pennsylvania Counties (Gray Bar Equals Average Death Rate of 
Rural Pennsylvania Counties)  
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In Pennsylvania, the percent increase in the number of deaths was larger in rural counties 
(42%) than urban counties (34%) between 2015 and 2016.18 In 2016, 77% of fatal overdoses across 
the Commonwealth involved white individuals, 12% involved black individuals, and 7% Hispanic 
individuals. For the first time, fentanyl-related synthetic opioids were the leading cause of 
overdose-related death in both rural and urban Pennsylvania counties.18 In 2016, fentanyl-related 
synthetic opioids were associated with 52% of the deaths, increasing from 27% in 2015. There was 
a 150% increase in fentanyl-related synthetic opioid-related deaths from 2015 to 2016. Heroin was 
the second most common drug category, followed by prescription opioids in rural counties, and 
benzodiazepines in urban counties.18  
2.2 METHODS OF TREATMENT AND PREVENTION 
2.2.1 PRIMARY PREVENTION EFFORTS 
State and national programs have focused on primary prevention efforts and improved access to 
effective opioid treatment in response to the increase in overdose deaths. Primary prevention 
efforts arecentered on decreasing the number of individuals who misuse opioids and mitigating 
access to opioids. Most commonly, primary efforts consist of educational programs aimed at the 
most high-risk populations for overdose, such as those with a history of SUD or young adults.37 
Another example of primary prevention efforts are PDMPs. The Pennsylvania-PDMP has been 
attributed with an 86% decrease in “doctor shopping,” the action of visiting multiple healthcare 
providers and filling the same prescription for the same reported injury or illness.38 Given the 
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recent implementation of the Pennsylvania-PDMP, begun in 2016, it is still too early to quantify 
the outcomes of such a program on the population in respect to reduction in drug overdose.38   
Another primary prevention strategy are drug take-back programs. They allow the safe 
disposal of prescription and over-the-counter solid medications, tablets and capsules, and pet 
medications. 39 Drug take-back programs serve multiple purposes through proper disposal of 
medications. These programs have been implemented throughout communities to provide a safe 
and secure place for people to return unused prescription medications. This provides an 
opportunity to reduce the amount of opioids available in a community so that they cannot be 
misused or accidentally consumed, by children, for example.40 In Pennsylvania, the Department 
of Drug and Alcohol Programs sponsors prescription drug take-back programs throughout the 
Commonwealth. However, the effects of these types of strategies on the opioid epidemic have not 
yet been determined.41 
2.2.2 DRUG AND ALCOHOL TREATMENT   
To determine the level of care necessary to treat an individual with an SUD in Pennsylvania, 
healthcare workers assess patients using the Pennsylvania Client Placement Criteria (Figure 3).42 
The four levels of care in the Pennsylvania Client Placement Criteria include (1) Outpatient and 
Intensive Outpatient Treatment; (2) Partial Hospitalization and Recovery Residence; (3) 
Medically-Monitored Inpatient Treatment; and (4) Medically-Managed Inpatient Treatment. 
These four levels of drug and alcohol treatment differ in their level of monitoring, frequency, use 
of medications, and whether or not they require that the participant reside as an inpatient or return 
for treatment as an outpatient. The types of care described in Figure 3 specifically apply to 
individuals in recovery from drug and alcohol misuse or those diagnosed with an SUD. Recovery 
12 
is defined by the SAMHSA as “a process through which individuals improve through health and 
wellness, live self-directed lives and strive to reach their full potential.”43  
Figure 3: The Four Patient Care Levels Suggested by the Pennsylvania Client Placement Criteria 
In Pennsylvania, the Department of Drug and Alcohol Programs and the Department of 
Human Services have established different entities to help connect patients to SUD and OUD 
treatment services. Each county, or groups of counties, has Single County Authorities. The Single 
County Authority determines a person’s eligibility for service funding, assesses his/her need for 
various types of treatment or other medical services, and refers the individual to programs that 
match his/her needs.44 In 2017, Centers of Excellence were established throughout the 
Commonwealth specifically to manage the influx of OUD patients during the onset of the opioid 
epidemic. Centers of Excellence ensure that people with OUD engage in different forms of 
treatment through case management, and assist patients in overcoming barriers, such as lack of 
transportation and childcare services.45  
Level 1
• Outpatient and Intensive Outpatient Treatment
• Ex: 5 hours of outpatient drug and alcohol treatment per week
Level 2
• Partial Hospitalization and Recovery Residence
• Ex: 3 days of partial hospitalization per week
Level 3
• Medically-Monitored Inpatient Treatment
• Ex: 24-hour observation, monitoring, and medication; full resources of
acute care, general hospital is not neccesary
Level 4
• Medically-Managed Inpatient Treatment
• Ex: 24-hour medically-directed detoxification in an acute care setting;
medical services and full hospital resources are available 
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2.2.3 MEDICATION ASSISTED TREATMENT    
Medication Assisted Treatment (MAT) is an effective strategy to reduce the chances of an opioid 
overdose.46 MAT uses medications, such as buprenorphine, methadone, naltrexone, and naloxone, 
that can help prevent relapse. These medications can be used alone or in a combination as either 
full agonists, (e.g., methadone), partial agonists (e.g., buprenorphine), or antagonists (e.g., 
naltrexone and naloxone) on the mu, kappa, or delta opioid receptors.23 Opioid agonist therapies, 
such as methadone and buprenorphine, work by reducing the effects of opioid withdrawal. 
Buprenorphine, a partial-opioid receptor agonist, partially binds to and activates the receptors but 
more weakly than a full agonist, such as methadone or heroin. As a result, opioid agonists can 
relieve symptoms of withdrawal and cravings. Opioid antagonist therapies work by reducing the 
risk of relapse and the urge to use drugs by fully blocking the receptor’s ability to be activated by 
an agonist, such as heroin.47 When a patient is actively taking an opioid antagonist and consumes 
an opioid, the opioid will not cause pain relief or euphoria.  
It is often clinically recommended to begin MAT using opioid-agonist methods and 
transition the patient to opioid-antagonist methods.48 MAT has been shown to improve patient 
outcomes, such as decreasing the frequency of problematic opioid use, HIV transmission, and 
mortality rates.37 In addition, this course of treatment allows for the patient to slowly be 
transitioned off of an opioid in order to ease withdrawal, while eventually using the opioid-
antagonist therapy to decrease potential future cravings.   
A common barrier to provider participation in MAT programs is the stigma associated with 
the therapy and stigma associated with placing treatment clinics in communities.37 Some local 
officials have opposed locating MAT programs in their neighborhoods by proposing legislation 
that is in violation of the Americans with Disabilities Act that would change zoning codes to 
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exclude MAT centers.49 Health insurers have also imposed arbitrary limits on how long a provider 
can treat OUD using medications.49,50 For example, some insurers have limited OUD treatment 
with methadone and will not continue payment for treatment that exceeds a certain time period.51  
A second barrier to physicians providing MAT using buprenorphine or methadone is the 
additional training mandated by the Drug Enforcement Administration, which prohibits doctors 
from prescribing MAT therapy if they are not certified.52 For example, to become a buprenorphine 
provider, a physician or advanced practice provider must take an additional either eight- or 24-
hour continuing education course to prescribe the medication for patients.53 The extra time 
commitment and process may seem overly burdensome to providers and they may decide to avoid 
becoming certified to work with the medication.52,54 As of January 2018, providers can prescribe 
buprenorphine for up to 30 patients for the first year after initially obtaining their waiver. 
Following the first year, providers can apply to prescribe buprenorphine for 100 and then 250 
patients at a time. This will increase the access to the medication, allowing providers to treat more 
patients in rural and urban areas.53     
2.2.4 BEHAVIORAL THERAPY  
Several forms of behavioral therapy are recommended by healthcare professionals for the 
management of OUD. Cognitive-Behavioral Therapy was first developed as a method to prevent 
relapse when treating alcohol use disorder patients. Cognitive-Behavioral Therapy strategies are 
based on teaching individuals how to identify and correct problematic behaviors, such as drug 
misuse and corresponding behaviors, by using a specific skillset, such as coping skills.55 
Techniques used in Cognitive-Behavioral Therapy include discussing the positive and negative 
consequences of continued drug use, self-monitoring by patients to recognize cravings and address 
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them early on, and learning how to develop strategies that remove the individual from situations 
where the patient might be tempted to use the substances.  
A second type of behavioral therapy used to manage SUDs is contingency management 
(CM).55-58 CM involves administering rewards to reinforce positive behaviors, such as abstaining 
from using drugs and alcohol. CM has been shown to be effective at increasing treatment efficacy 
and retention in methadone and psychosocial counseling treatment programs.57 Voucher-Based 
Reinforcement and Prize Incentives CM are two examples of CM. In Voucher-Based 
Reinforcement, the patient receives a voucher for each drug-free urine test they have. The value 
increases in monetary value as the patient progresses through treatment. Prize Incentives CM is 
similar to Voucher-Based Reinforcement CM; however, the patients have opportunities to win 
certain prizes instead of monetary vouchers. These methods of behavioral therapy can augment 
traditional behavioral therapies and have been shown to be effective in promoting abstinence from 
opioids and cocaine (co-use) in patients in methadone treatment specifically.58  
2.2.5 HARM REDUCTION STRATEGIES 
There has also been a large increase in the use of harm reduction strategies to reduce overdose 
deaths. Harm reduction strategies and programs aim to reduce the negative consequences 
associated with drug use, such as contracting hepatitis from a needle used to inject heroin 
intravenously.59 These programs have been implemented more frequently in recent years because 
of changes in policy around drug use and overdose. Many of these harm reduction programs have 
been based on naloxone distribution and drug take-back programs.37 Naloxone is an opioid 
antagonist that has the ability to reverse an overdose and save an individual’s life. Naloxone can 
be administered by first responders, lay persons, and medical providers. It is often distributed in 
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areas that have high rates of overdose.60 Opioid overdose prevention programs provide training to 
lay persons in the community on how to identify the symptoms of an opioid overdose and how to 
respond by administering naloxone.61  
In comparison to MAT and other treatments, less research exists on the impact of education 
and community naloxone distribution programs on opioid overdoses and mortality. Studies have 
focused on training and distributing naloxone kits to individuals on heroin through community-
based programs. These programs have been successful because heroin users often use with others. 
If someone overdoses, an individual is present to administer naloxone and reverse the overdose.62 
Importantly, communities where these programs were implemented saw a reduction in opioid 
overdose death rates. The Medical Examiner of Cook County and Chicago, Illinois reported a 20% 
decrease in opioid-related overdoses in 2001 and 10% decreases in 2002 and 2003, following the 
institution of a naloxone distribution education harm reduction campaign in January of 2001.63 
2.3 PENNSYLVANIA COUNTY ANALYSIS 
Tables 1 and 2 display the drug-related overdose death rate in 2016 (per 100,000, crude), the 
number of drug-related overdose deaths in 2016, the rate (per 100,000) of waivered buprenorphine 
providers, the rate (per 100,000) of drug and alcohol and mental health providers, and the rate (per 
100,000) of inpatient and outpatient detoxification service providers currently registered in each 
county of Pennsylvania as of January 2018 separated by urban (Table 1) and rural (Table 2) 
counties.  
The categories of drugs included in the 2016 Drug Enforcement Agency Death Report, 
include benzodiazepines, cocaine, fentanyl, fentanyl-related substances, non-prescription 
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synthetic opioids, heroin, other illicit drugs (e.g., methamphetamine), and prescription opioids. 
Beaver County had the highest overdose death rate of all urban counties in Pennsylvania in 2016 
at 59.81 deaths per 100,000 (crude). Out of all the counties in Pennsylvania, Fulton and Cambria 
County had the highest death rates at 74.1 and 65.42 deaths per 100,000 people (crude) in 2016. 
Both counties are located in rural areas of the state as classified by the Center for Rural 
Pennsylvania. 
Table 1: The Number of Overdose Deaths, Overdose Death Rates, and Rate of SUD-Related Providers in Urban 
Counties per 100,000 people.  
Urban 
County 
Name 
Population 
(2010 
Census) 
# of 
Overdose 
Deaths 
(2016) 
Overdose Death 
Rate (per 100,000) 
(2016) 
(crude) 
Rate of 
Buprenorphine 
Providers 
(2018) 
Rate of 
D&A and 
MH* 
Providers 
(2018) 
Rate of 
Detox 
Service 
Providers 
(2018) 
Allegheny 1223348 648 52.97 16.02 8.26 0.33 
Beaver 170539 102 59.81 8.80 6.45 1.17 
Berks 411442 117 28.44 6.32 8.99 0.97 
Bucks 625249 168 26.87 8.00 6.08 0.64 
Chester 498886 97 19.44 6.21 7.62 0.60 
Cumberland 235406 58 24.64 3.40 5.10 0.00 
Dauphin 268100 84 31.33 4.10 10.82 0.37 
Delaware 558979 206 36.85 8.94 3.40 0.36 
Erie 280566 90 32.08 7.84 9.62 0.71 
Lackawanna 214437 84 39.17 9.33 7.00 0.93 
Lancaster 519445 116 22.33 4.62 5.97 0.58 
Lebanon 133568 16 11.98 2.25 7.49 1.50 
Lehigh 349497 134 38.34 6.29 7.15 0.29 
Luzerne 320918 140 43.62 11.22 5.92 1.25 
Montgomery 799874 230 28.75 10.50 6.25 0.63 
Northampton 297735 70 23.51 4.70 5.71 0.67 
Philadelphia 1526006 907 59.44 11.27 10.42 0.92 
Westmoreland 365169 174 47.65 15.06 7.12 0.55 
York 434972 127 29.2 4.37 6.44 0.69 
Source: 2016 Drug Enforcement Administration Report Based on Pennsylvania Coroner/Medical Examiner Data  
*Mental Health (MH) 
 
 
 
 
 18 
Table 2: The Number of Overdose Deaths, Overdose Death Rates, and Rate of SUD-Related Providers in Rural 
Counties per 100,000 people.  
Rural 
County Name 
Population 
(2010 Census) 
# of 
Overdose 
Deaths 
(2016) 
Overdose 
Death Rate 
(per 100,000) 
(2016) 
(crude) 
Rate of 
Buprenorphine 
Providers 
(2018) 
Rate of 
D&A and 
MH* 
Providers 
(2018) 
Rate of 
Detox 
Service 
Providers 
(2018) 
Adams 101407 28 27.61 6.90 4.93 0.00 
Armstrong 68941 41 59.47 2.90 8.70 0.00 
Bedford 49762 11 22.11 0.00 6.03 0.00 
Blair 127089 43 33.83 11.80 9.44 2.36 
Bradford 62622 17 27.15 1.60 9.58 0.00 
Butler 183862 74 40.25 30.46 7.61 0.54 
Cambria 143679 94 65.42 4.87 5.57 0.00 
Cameron 5085 0 0 19.67 19.67 0.00 
Carbon 65249 17 26.05 10.73 10.73 0.00 
Centre 153990 20 12.99 9.09 9.09 0.65 
Clarion 39988 7 17.51 2.50 7.50 0.00 
Clearfield 81642 11 13.47 7.35 11.02 0.00 
Clinton 39238 10 25.49 10.19 5.10 0.00 
Columbia 67295 18 26.75 2.97 13.37 0.00 
Crawford 88765 32 36.05 5.63 10.14 1.13 
Elk 31946 3 9.39 3.13 15.65 0.00 
Fayette 136606 60 43.92 10.98 10.98 0.73 
Forest 7716 0 0 0.00 25.92 0.00 
Franklin 149618 39 26.07 4.68 6.02 0.00 
Fulton 14845 11 74.1 6.74 6.74 0.00 
Greene 38686 19 49.11 7.75 15.51 0.00 
Huntingdon 45913 7 15.25 0.00 6.53 0.00 
Indiana 88880 45 50.63 10.13 5.63 1.13 
Jefferson 45200 7 15.49 11.06 8.85 0.00 
Juniata 24636 4 16.24 8.12 4.06 0.00 
Lawrence 91108 40 43.9 9.88 7.68 0.00 
Lycoming 116111 34 29.28 14.64 8.61 0.00 
McKean 43450 7 16.11 4.60 23.01 2.30 
Mercer 116638 31 26.58 10.29 11.15 0.00 
Mifflin 46682 6 12.85 12.85 6.43 0.00 
Monroe 169842 41 24.14 8.24 8.24 1.18 
Montour 18267 5 27.37 27.37 10.95 0.00 
Northumberland 94528 27 28.56 5.29 8.46 0.00 
Perry 45969 9 19.58 0.00 2.18 0.00 
Pike 57369 10 17.43 8.72 5.23 0.00 
Potter 17457 2 11.46 0.00 17.19 0.00 
Schuylkill 148289 59 39.79 1.35 6.74 0.67 
Snyder 39702 3 7.56 0.00 5.04 0.00 
Somerset 77742 21 27.01 1.29 6.43 1.29 
Sullivan 6428 1 15.56 0.00 0.00 0.00 
Susquehanna 43356 8 18.45 0.00 4.61 0.00 
Tioga 41981 6 14.29 4.76 16.67 4.76 
Union 44947 7 15.57 0.00 11.12 2.22 
Venango 54984 9 16.37 7.27 16.37 1.82 
Warren 41815 0 0 2.39 26.31 2.39 
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Rural 
County Name 
Population 
(2010 Census) 
# of 
Overdose 
Deaths 
(2016) 
Overdose 
Death Rate 
(per 100,000) 
(2016) 
(crude) 
Rate of 
Buprenorphine 
Providers 
(2018) 
Rate of 
D&A and 
MH* 
Providers 
(2018) 
Rate of 
Detox 
Service 
Providers 
(2018) 
Table 2 Continued  
Washington 207820 106 51.01 16.84 8.66 0.48 
Wayne 52822 17 32.18 5.68 7.57 0.00 
Wyoming 28276 7 24.76 3.54 10.61 0.00 
Source: 2016 Drug Enforcement Administration Report Based on Pennsylvania Coroner/Medical Examiner Data  
*Mental Health (MH) 
2.4 RURAL VERSUS URBAN CLASSIFICATION 
Rural and urban regions of Pennsylvania differ demographically and by population density. The 
Center for Rural Pennsylvania’s definitions of “rural” and “urban” counties  are based on 
population density statistics.64 Population density is calculated by dividing the total population of 
a specific area by the total number of square land miles of that area. According to the 2010 Census, 
Pennsylvania’s overall population density is 284 persons per square mile. If a county has 284 
persons or more per square mile, it is considered urban. Following this definition, Pennsylvania 
has 48 rural counties and 19 urban counties (Figure 4).   
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Figure 4: Rural (in gray) and Urban Counties in Pennsylvania 
In 2016, Pennsylvania had an estimated population of 12,784,227 people and 1,470,338 
lived in rural Pennsylvania.65 While much of Pennsylvania is rural, the majority of the population 
lives in metropolitan or urban areas. Seven of Pennsylvania’s 67 counties have total populations 
that exceeded 500,000 in 2016. The four most populous counties are Philadelphia, Allegheny, 
Montgomery, and Bucks.65 This makes Pennsylvania a unique state in that there are both large 
urban and rural populations separated by large geographical distances.  
2.5 SOCIAL ECOLOGICAL MODEL 
One way to identify key differences and similarities in how OUD manifests and is addressed in 
rural and urban communities is to use a framework to identify key factors that affect a public health 
event. The SEM is a theory-based framework for understanding the interacting and multilayered 
effects of environmental and personal factors that ultimately impact behavior. It can be used to 
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identify areas of interest from an organizational or behavioral perspective that may impact the 
overall health of a population.66 The SEM is made up of five nested and hierarchical levels: 
Individual, Interpersonal, Community, Organizational, and Policy.67  
The individual level is defined as the characteristics of an individual that influence behavior 
change, like risk factors and perceived norms. The interpersonal level of the SEM is made up of 
the formal and informal social networks and support systems that can influence the individual’s 
behavior, such as family and the influence of one’s peers on their behavior. Community level 
factors consist of the environments or settings in which relationships occur. Organizational factors 
are the organizations and social institutions available or not available to the individual. Finally, the 
policy level impacts all of these nested levels by regulating and supporting actions and practices 
that influence an individual’s susceptibility to a health outcome.66,67  
In public health, the most effective programs will simultaneously address various levels or 
work to be designed so components are complementary.67 In this manner, the SEM can be used to 
explore a range of underlying factors that contribute to OUD in rural versus urban populations. 
The results section of this thesis is organized using this framework to differentiate between rural 
and urban populations as they relate to OUD. The SEM can be used to demonstrate that the opioid 
epidemic has deep roots in socio-economic factors both upstream and downstream of an event, 
such as an opioid overdose.   
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3.0  METHODOLOGY 
A literature search was conducted using PubMed, Google Scholar, and MedlinePlus for articles 
published from 1998 to 2018 related to opioids and the management of OUD following the factors 
classified using the SEM. A separate search was also conducted on providers of SUD related care, 
including buprenorphine prescribers and drug and alcohol and mental health treatment providers. 
The primary objective of the provider search was to determine the number of providers located in 
each county in order to calculate a rate of providers for rural and urban counties. During the 
literature review, addiction to prescription opioids, synthetic opioids, and heroin were all 
considered. Articles, studies, and information included in this thesis pertain only to the United 
States. 
3.1 LITERATURE SEARCH 
The primary objective of the literature search was to determine differences in rural and urban 
populations as they pertain to various factors affecting OUD and related behaviors. The SEM 
guided the literature search process. Key words related to the SEM were combined with SUD-
related terms during the search as they pertain to both rural and urban communities. Keywords 
related to the levels of the SEM were “skills,” “perceived norms,” “genetics,” “risk factor,” “peer 
influence,” “social network,” “family,” “socioeconomic,” “recovery support services,” “stigma,” 
“treatment access,” “healthcare insurance,” “healthcare access,” “standing order,” “federal 
legislature,” and “state legislature.” Keywords related to opioids were “opioid use disorder,” 
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“substance use disorder,” “opioid,” “opiate,” “heroin,” “prescription,” “medication assisted 
treatment,” “behavioral therapy,” “mental health,” and “policy.” Other MeSH terms including 
“rural,” “urban,” and “treatment,” were combined with the terms used for opioids and the 
management of OUD as well as the terms related to the SEM. The word “difference” was also 
used as a MeSH term to search for differences between urban and rural populations. The keywords 
related to opioids follow the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
criteria for the classification of mental disorders used by mental health professionals in the United 
States.  
A total of 4,325 articles were identified through database searching for analysis in the 
results section of this paper. These articles include the keywords outlined above that relate to OUD, 
SUD, and the SEM. Thirty-two articles were identified through other sources, such as Google 
Scholar manual searches. A total of 2,361 articles were removed due to duplicate citations that 
occurred following the database searches. Two-thousand three-hundred and sixty-one articles were 
screened and 2,177 were removed from the resource database. Articles were briefly screened for 
publishing dates (after 1998) and titles and subjects that related to the purpose of this thesis. If 
articles were published before 1998 they were excluded. This time frame was chosen so that more 
recently published literature was included in this thesis. Any articles that appeared useful to 
addressing the objectives of the thesis were kept in the resource database. One-hundred and eighty-
four full-text articles were assessed for eligibility by review of their abstract. Abstracts were 
reviewed for pertinent subject matter, such as rural and urban differences in levels of access to 
treatment options for OUD. A total of 107 full-text articles were excluded due to irrelevant subject 
matter or weak contextual results. These results were determined too weak or strong based on the 
level of statistical significance of the results, if available. If statistical analysis was not available, 
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the literature available that supported each claim was reviewed and analyzed for its significance 
and relevance. Irrelevant subject matter included topics not outlined in the SEM. If the full-text of 
the article was not available, the article was excluded. Seventy-seven articles were included in the 
qualitative synthesis of the results section of this thesis (see Appendix for PRISMA Flow 
Diagram). Information obtained from research studies and other sources included study outcomes, 
background information related to opioids, and evidence-based treatment methods for OUD and 
related SUDs, such as alcohol use disorder.  
The literature was thematically analyzed using a three-step process to determine the factors 
outlined in this paper. First, the literature was coded using the five levels of the SEM as codes. 
From here, grounded theory methodology was used to identify key factors that relate to each level 
of the SEM. This step consisted of reviewing each piece of literature’s abstract and results section 
for its themes for relevance to the opioid epidemic. Common themes related to healthcare access, 
common misconceptions about people with SUD and OUD, stigma, and differences in rural and 
urban populations. Factors were generated from the themes or the themes themselves were used 
as factors and then organized using the SEM. Finally, the information was coded as relating to 
either urban or rural communities.  
3.2 PROVIDER SEARCH 
In order to determine the availability of treatment resources in each county, a search for the number 
of providers in each county was conducted. The SAMHSA provider locator search function was 
used to search for buprenorphine providers, detoxification service providers, and drug and alcohol 
and mental health service providers registered in the Commonwealth of Pennsylvania. The 
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SAMHSA provider locator tool (https://findtreatment.samhsa.gov/) can be used to find various 
recovery and treatment centers by their location anywhere in the United States. A buprenorphine 
provider was included if registered with SAMHSA by January 2018. Drug and Alcohol or Mental 
Health providers were included if registered with SAMHSA as of January 2018.  
The provider searches started at the level of the entire United States. Pennsylvania was then 
selected as the state of interest to the search. Next, each county in Pennsylvania was selected and 
the three relevant provider types were searched using the locator tool. Following each search, a 
Microsoft Excel spreadsheet was downloaded and analyzed for the presence of each provider type 
in each Pennsylvania County.  Provider rates by county were calculated by dividing the population 
of each county in 2010 by the number of providers and multiplying the figure by 100,000. 
Information extracted about access to different types of treatment and providers throughout 
Pennsylvania included information on the number of registered buprenorphine providers, 
providers of any type of detoxification related services, and providers of any type of drug and 
alcohol and/or behavioral healthcare. 
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4.0  RESULTS 
The factors relevant to each level in the SEM were determined based on the review of the literature 
conducted in the background section of this paper as well as those cited as pertinent to the various 
levels by the Centers for Disease Control and Prevention.67,68 At the individual level, risk factors, 
and perceived norms were identified as playing a part in increasing an individual’s susceptibility 
to OUD. Family, social networks, and the influence of one’s peers were identified as being an 
integral part of the interpersonal level of the SEM. The community level included the recovery 
support services available to individuals with OUD, socioeconomic status, occupation, the stigma 
against SUD individuals, and the treatment of SUD in communities. Healthcare access, treatment 
options, and insurance were included as factors at the organizational level. In the policy level of 
the SEM, state and federal policies were considered.  
Common factors not included in any of the levels for this analysis include the media and 
educational and workplace-related policies and procedures.68 This is because the effect of the 
media on SUD and OUD is too difficult to interpret, and the literature is lacking on educational 
and workplace related policies to outcomes related to SUD or OUD. The media can be included in 
the SEM at various levels, such as the Community and Organizational level. The following will 
define and detail the evidence behind each of these factors and how they relate to urban versus 
rural communities. Figure 5 shows the SEM level and the factors identified following a review of 
the literature.  
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Figure 5: Social Ecological Model, Factors that Contribute to Opioid Overdose 
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4.1 INDIVIDUAL LEVEL  
4.1.1 OPIOID USE DISORDER RISK FACTORS 
Several risk factors and comorbidities increase an individual’s risk of OUD. These include past or 
current substance misuse, mental health disorders, and family history.69 Opioid-related fatal 
overdose is highest in adults aged 25-54 who are white and have co-occurring SUDs and mental 
health disorders.28 Family, twin, and adoption studies have shown that genetic factors contribute 
to OUD-related behavior(s) and increase the chances of relapse after treatment through interactions 
with environmental factors. These include a history of substance misuse, depression and other 
psychiatric disorders, childhood abuse, and certain personality traits, such as impulsivity and 
sensation seeking.70 These risk factors do not vary between rural and urban populations based on 
a review of the literature.  
4.1.2 PERCEIVED NORMS 
An individual’s health-related behavior is often guided by how they perceive others’ beliefs and 
behaviors. A norm is the perceived social pressure to enact or not to enact a behavior in a 
situation.71 College students often perceive social pressure to drink alcohol illegally or use drugs, 
due to the prevalence and pressure to be a part of the collegiate social system. This can lead to 
negative impacts, such as arrest, or alcoholism or drug addiction after repeated use. Drug and 
alcohol users often share a group identity that affects their behavior and risk for SUD.72 They 
perceive that drug and alcohol use is normal and that they should take part in the activity. Research 
has shown that there is a relationship between actual behavior and perceived peer norms.73 These 
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perceived norms do not vary between rural and urban populations based on a review of the 
literature.  
4.2 INTERPERSONAL LEVEL  
4.2.1 FAMILY  
Family environment can play a large role in an individual’s decision to use and misuse drugs and 
alcohol. At a young age, people are greatly influenced by their parents. Evidence has shown that 
family processes play a vital role in social and behavioral outcomes among youth and/or in 
protecting them from negative results.74 Adolescents who have conflicts in their home life are more 
likely to consume alcohol at a young age. The attitudes and beliefs that family members have 
towards SUDs also greatly impact an individual’s fight to get sober or seek treatment. For example, 
if a family member sees SUD as a moral failing and that the person should “just quit,” the 
individual with SUD may struggle to find and stay in an SUD treatment program.75 If a family is 
well-educated on the subject and provides a good attitude for the family member, research shows 
that the individual has a greater opportunity to be successful in treatment.76 Consequential to the 
development of OUD, people often divert their opioid prescription medication to family 
members.77-82 Therefore, family environment can play multiple roles in the potential development 
of OUD. However, the effect of family on OUD does not vary between rural and urban populations 
based on a review of the literature.   
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4.2.2 SOCIAL NETWORKS 
An individual’s social network greatly impacts their risk for misusing drugs and alcohol as well as 
developing an SUD. A social network is a network of individuals, such as friends and coworkers, 
that are connected through interpersonal relationships.83 In a study examining the effect of social 
relationships and social assimilation in adult Latinos on SUDs, it was found that SUD is associated 
with more frequent interactions with friends in females but not males.84 Other research has shown 
positive associations between increased substance use with friend and family encouragement of 
use and having close members in their social network who used substances. Importantly, peer 
discouragement was associated with reduced risk for SUD.85   
The population of rural areas is often more dispersed and spread out geographically than 
in urban areas. However, rural communities are often strong from a social perspective. People 
often know each other by name and the community is “tight-knit” in nature.86 These strong 
community ties in rural areas reflect the emphasis the community puts on strength and social 
capital.87 Individuals in rural areas report knowing the members of their social networks for a 
longer period of time than those in urban areas.88 Research on rural populations has also shown 
that these individuals trust their neighbors more and are more likely to reach out to them compared 
to those in more urban geographical places.89,90 Therefore rural individuals may be more able to 
intervene in the case of an opioid overdose because they may be more available to help in an 
emergency situation. Social networks have the potential to impact rural communities in a more 
positive way than urban communities.  
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4.2.3 PEER INFLUENCE 
Individuals with SUD often associate with people with SUDs. The influence of friends and peers 
is often a large aspect of an individual’s substance use and misuse. Research shows that adolescents 
with fewer than four friends who require alcohol or drug treatment have a greater likelihood of 
remaining abstinent.91 The most important contributors to adolescents using tobacco and 
consuming alcohol are having friends who smoke or drink and being invited to drink or smoke.92 
Peer influence and its effects on SUD occurs in adolescents and adults in both rural and urban 
areas.93  
4.3 COMMUNITY LEVEL  
4.3.1 STIGMA 
Stigma plays an important role in the opioid epidemic. Several factors contribute to the stigma 
associated with OUD and its treatment.49 First, individuals may feel as though OUD is a moral 
weakness or choice and not a mental illness.50 This creates a stigma against both the SUD patient 
population as well as the treatment methods. Second, the language around SUDs and OUD is often 
very stigmatizing. Words like “addict” and “drug abuser” often implicate the person and create a 
negative connotation that can be difficult to overlook. For example, people who have OUD are 
often referred to as “junkies.”  Urine drug tests are called “clean” or “dirty,” rather than “positive” 
or “expected.” This type of stigmatizing language propagates throughout society and leads to 
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detrimental effects on the SUD patient population.49 Stigma can make it more difficult for an 
individual to obtain treatment for their disease as well as find or keep a job.94  
Stigma against opioid users, prevention efforts, and treatment methods is present in both 
rural and urban populations. A major barrier to the implementation of MAT programs in both 
populations is preexisting provider attitudes about patients with addiction and about treatment 
strategies. To overcome this barrier, extensive training with office staff and providers is required 
to reduce the negative perceptions towards this patient population.95 For example, methadone 
treatment, has been shown to be stigmatized by clinical staff.96-98 Stigma is present in both rural 
and urban populations based on a review of the literature.  
4.3.2 RECOVERY SUPPORT SERVICES 
Recovery support services are non-clinical services that increase the efficacy of treatment and 
support individuals to reach their goals. These commonly consist of transportation to and from 
treatment, patient education to navigate barriers of health literacy, peer-to-peer mentoring, and 
support groups.99 While there are Centers for Community Resources available in all Pennsylvania 
counties, rural areas have fewer recovery support services than urban areas in general, thus 
magnifying the barriers in these communities for receiving treatment.100 Community resources and 
support services can be essential to an individual’s successful recovery from an SUD.101  
4.3.3 OCCUPATION 
The nature of the work that someone performs for a living wage is often based on the skills that 
they possess from a young age. In the workforce in Pennsylvania and United States, people skilled 
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in manual labor have increased odds of acute and chronic injury. Injury can lead to opioid 
prescriptions to treat the pain associated with the injury and chronic prescriptions for opioids are 
associated with OUD.102 Common examples of these jobs include, farming, mining, and 
manufacturing. In comparison, someone who works at a desk job on a regular basis is at less risk 
of personal injury.103 
In rural areas, the population is more often skilled in manual labor-type skills than non-
manual labor type skills.104 The long-term action of manual labor wears on the body physically, 
and it often leads to chronic pain.105 The chronic pain that develops can lead to opioid use and 
potentially OUD in the long term.102 Adults in manual labor have also been shown to have higher 
rates of prescription opioid misuse. These adults should be monitored more closely for chronic 
pain opioid use.106   
Geographic variation in the prevalence of opioid prescriptions is large, and the counties 
with the highest prescribing rates for opioids were disproportionately located in Appalachia, 
southern, and western states.107 It has been suggested that this is due to several factors. Rural 
populations tend to be older than urban populations on average.108 These populations experience 
an increase in chronic pain, which can lead to an increase in opioid prescriptions. Research also 
shows that chronic pain and injury are higher in rural than urban areas.109 Other research in rural 
areas has shown that prescription drug use is a part of the culture due to the high number of 
prescriptions prescribed to coal mine workers and other labor intensive jobs for decades.110 This 
large amount of opioids in rural areas creates the opportunity for diversion and other illegal trading 
of prescription medications for nonmedical use.77 Nationally, representative surveys have also 
indicated that nonmedical use of prescription opioids is higher in rural communities than urban.111-
115  
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4.3.4 SOCIOECONOMIC STATUS  
Socioeconomic status (SES) is defined as the social standing or class of an individual or group of 
people. It can be measured as a combination of income, education, and occupation.116 Low SES is 
associated with increased drug and alcohol use among other risk factors.117,118 In Pennsylvania, the 
rural poverty rate is 13.8% compared with 12.8% in urban parts of the Commonwealth.65 The 
decrease in wages for low-skilled jobs and demand for manufacturing jobs and the corresponding 
increase in need for higher skilled workers are affecting rural areas more negatively than urban 
areas, given the present population workforce and its skillbase119-121 The combination of these 
stressors can cause an individual to have a low SES and increases the opportunity for drug and 
alcohol use to occur.120,122 The effect of low SES on OUD is the same on rural and urban 
populations because there are populations of low SES in both rural and urban communications.123  
4.4 ORGANIZATIONAL LEVEL  
4.4.1 HEALTHCARE ACCESS 
Primary, emergency, and specialist healthcare access is vital for any population. Low access to 
healthcare services is often associated with an increase in disease rates.124 In rural areas, there is 
less access to healthcare services than in urban areas, including primary medical care, emergency 
care, and other specialty medical service providers like behavioral healthcare workers. Around 
20% of the population of the United States lives in a rural area. However, only about 9% of the 
nation’s physicians work in rural communities.125 Medical schools often do not have as strong a 
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relationship with rural areas as they do with urban environments. Once they graduate, few students 
are willing to work in rural areas.125-127 Also, 26 states have seen at least one rural hospital close 
since 2010. As of January 2018, two rural hospitals have closed in Pennsylvania since 2010.128   
Transportation is often seen as a major barrier to healthcare access. Barriers to 
transportation can lead to rescheduled or missed appointments, prolonged care, and misuse of 
prescribed medication. These can all lead to the mismanagement of illness and harm to patients.124 
Research on SUD patients found that transportation was a major barrier to individuals receiving 
effective treatment and recovering from illness.129 In addition to transportation, structural barriers 
limit an individual’s ability to access care. These consist of social, political, legal, and government-
run service systems.130 Rural areas have fewer mass transit systems funded by governmental 
agencies, such as bus systems and rail systems that further limit transportation.131  
4.4.2 TREATMENT OPTIONS 
In order to effectively manage SUDs and OUD, various methods of treatment need to be available 
for a person to be successful. Methods that benefit individuals in their recovery from a SUD 
include various types of drug and alcohol treatments, behavioral health treatment, and MAT. 
Research on SUD treatment utilization between 2005 and 2013 found that of persons with OUD, 
26% used some type of alcohol or drug use treatment, and 19% used opioid-specific treatment, 
such as MAT. The same study found that out of all alcohol and drug use treatments, self-help 
groups and outpatient rehabilitation treatment were the most commonly used services.132  
Figure 6 shows the rate (per 100,000) of drug and alcohol and/or behavioral health 
providers in each county throughout Pennsylvania as of January 2018. The rates of drug and 
alcohol and mental health service providers are similar in rural counties and urban counties. Two 
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major urban Pennsylvania counties, Allegheny and Philadelphia, have over one hundred times the 
drug and alcohol and/or behavioral health providers than in many rural counties. This poses a 
barrier to individuals in recovery for OUD who live in both rural and urban counties.  
 
 
Figure 6: Rates of Drug and Alcohol and/or Behavioral Health Providers in Each County of Pennsylvania in 
January 2018 
There are also lower rates of MAT providers who can prescribe buprenorphine for OUD 
in rural populations. Figure 7 shows the rate (per 100,000) of buprenorphine providers in each 
county of Pennsylvania as of January 2018. Susquehanna, Forest, Sullivan, Huntingdon, Perry, 
Bedford, Snyder, and Union Counties do not have any buprenorphine providers as of January 2018, 
while Allegheny and Westmoreland counties have 16 and 15 registered buprenorphine providers 
per 100,000 people, respectively. This means that individuals who live in these rural counties may 
need to travel a longer distance to receive care.  
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Figure 7: Rates of Registered Buprenorphine Providers in Each County of Pennsylvania in January 2018 
Nationwide, 82% of the rural population lives in a county without a detoxification center.133 
In Pennsylvania, there are fewer inpatient and outpatient detoxification providers and treatment 
providers in rural areas than urban areas. Figure 8 shows that 34 rural counties do not have any 
detoxification providers for someone to recover from opioid withdrawal. There is one urban county 
(Cumberland County) that does not have a single detoxification provider. In the most populated 
urban counties of the Commonwealth, Allegheny and Philadelphia, the rate of detoxification 
providers are 0.33 and 0.92, respectively. If an individual cannot be seen at a detoxification center 
they are often sent to an emergency rooms for detox.134 The lack of treatment centers and providers 
means that people are left on long wait-lists for treatment.135  
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Figure 8: Rates of Drug-Related Detoxification Service Providers in Each County of Pennsylvania in January 2018 
The availability of a detoxification provider or a hospital to medically manage withdrawal 
can vary depending on the type of insurance that someone has. For example, in Pennsylvania, if 
an overdose survivor is in a hospital and has private insurance, he/she can usually receive a bed in 
one day. If the same individual has county funding or Medicaid, they may have to wait five or six 
days to receive inpatient treatment.136 While these individuals are waiting for treatment, they have 
a higher potential of overdose due to the increased likelihood of continued drug use. If that 
overdose does occur, there may not be an opportunity to reverse the overdose because of the lack 
of trained people to administer naloxone and general decreased access to naloxone in rural 
communities.137 These wait times for treatment due to availability issues are an additional barrier 
to accessing treatment in a timely manner.138  
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4.5 POLICY LEVEL  
4.5.1 FEDERAL LEGISLATIVE POLICY 
The Comprehensive Addiction and Recovery Act (P.L. 114-198) was signed into law by President 
Barack Obama in 2016.139 It was enacted in response to the opioid epidemic and encompasses 
prevention, treatment, recovery, law enforcement, criminal justice reform, and harm reduction 
overdose reversal strategies. It established a coordinated approach for a combination of methods 
to aid in the treatment and recovery of OUD.140 The funds were equitably distributed to urban and 
rural geographical populations.  
 
4.5.2 STATE LEGISLATIVE POLICY 
In Pennsylvania, David’s Law (Opioid Overdose Reversal Act 139) allows first responders to act 
as if they are a healthcare professional authorized to prescribe and administer naloxone to an 
overdosing individual whom they encounter. A provision of Act 139, known as the “Good 
Samaritan” law, provides individuals immunity from prosecution if they respond to and report the 
overdose of another person. The individual can provide his or her name and remain on the scene 
of the incident and not be arrested. However, it does not protect individuals from being prosecuted 
if they are in possession of illegal substances or drug-related paraphernalia when authorities arrive. 
The law does increase the availability of naloxone in the community by allowing individuals who 
have a friend or family member who may overdose in the future to obtain naloxone.  
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Research has shown that many overdoses are witnessed by others who would be willing to 
intervene.37 Good Samaritan laws have been created to protect those who report overdose events 
from prosecution, even if they were using drugs themselves.141 However, research has shown that 
individuals are concerned that law enforcement will still arrest them for drug paraphernalia or 
being in the possession of illegal substances, such as heroin or other drugs. This leads people to be 
hesitant to contact law enforcement in the event they witness someone overdosing.142,143 Therefore, 
these laws do not always have the desired effect on the community or on those in the social circles 
of people who use drugs. 
4.5.3 STANDING ORDERS  
Across the country, standing orders have been enacted by state and local officials to aid in overdose 
prevention efforts.144 A standing order allows a pharmacist or physician to write a prescription for 
certain medications to assist with opioid overdose prevention efforts. The recent standing order 
(PA DOH-002-2016) by Governor Tom Wolf also increases access to naloxone by allowing 
anyone to obtain it from a pharmacy.145 In both rural and urban areas, these life-saving policies are 
being implemented in a timelier manner than if the Commonwealth or federal legislature were to 
enact the law through the traditional process.144  
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5.0  DISCUSSION  
This review of the literature using the SEM identified several factors that are unique for rural and 
urban populations. Individual risk factors and perceived norms affect both populations in a similar 
manner. Family and peer influence were determined to equally affect both rural and urban 
populations at an interpersonal level. Stigma and SES affect both rural and urban communities. 
Policies affect both rural and urban populations equally but do not take the differences of rural 
populations into account.  
 Several factors affect rural populations more strongly than urban ones. The most significant 
factors are located at the organizational level. Rural populations have less access to OUD treatment 
providers than urban populations, like buprenorphine providers. Rural populations have fewer 
options for detoxification providers. Rural and urban areas have a similar rates of access to drug 
and alcohol and mental health providers. Transportation is a major barrier to obtaining care and 
many individuals must travel long distances to be treated for OUD and related comorbidities. There 
are also fewer recovery support services available to rural populations, which makes the recovery 
process for OUD even more difficult. At the community level, the occupation of an individual and 
employers in rural communities can increase rural populations’ chances of OUD moreso than 
urban populations. The social networks of an individual (interpersonal level) can be a positive on 
rural communities since social networks can be stronger than those in urban communities. Table 
3 summarizes the factors that affect rural and urban populations’ chances of OUD and potential 
overdose that were analyzed in this paper.   
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Table 3: Summary of Factors that Can Affect Rural and Urban Populations for OUD 
Level of SEM Similar Effect in Rural and Urban Populations 
Greater Effect in Rural 
Population 
Direction of 
Effect on Rural 
Communities 
Individual Risk Factors and Perceived Norms None N/A 
Interpersonal Family and Peer Influence Social Networks  Positive  
Community Stigma and SES Occupation and Recovery Support Services Negative  
Organizational 
Drug and Alcohol and 
Behavioral Health 
Providers 
Healthcare Access, 
Buprenorphine Providers, 
and Detoxification 
Providers 
Negative  
Policy Federal, State, and Stranding Orders None N/A 
 
Social networks were found to impact rural populations more strongly than urban 
populations. It was unexpected to find that social networks can have a positive outcome on 
overdose and OUD on rural populations. The “tight knit” nature of rural communities can be 
optimized in future interventions by focusing on the social networks of individuals who use drugs. 
For example, naloxone distribution campaigns can focus on recruiting and educating individuals 
who are in the same social circles of people who misuse drugs. At the conclusion of the 
intervention, naloxone kits could be distributed to the individuals. The participants will therefore 
be equipped with the knowledge and materials to save a life in their social circle and/or community. 
Accounting for and acknowledging positive differences in rural and urban populations can also 
assist in directing future interventions and policy.    
The factors outlined in this paper also interact to increase or decrease the risk of OUD and 
overdose in rural and urban populations. Risk factors at an individual level, such as family history 
of substance misuse and depression, intermix with factors at the interpersonal level, such as 
someone’s social network. Together these factors can combine to increase someone’s potential for 
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having an OUD.70,85 Low access to healthcare and treatment can also by magnified when combined 
with the lack of access to recovery support services and skills that support a primary profession of 
manual labor. Future policy can take all these factors into account to help overcome barriers in 
these different populations. On the other hand, ignoring these differences and not improving access 
to care ultimately increases the cost of healthcare and puts further burden on providers and health 
systems.136 
5.1 OVERCOMING STIGMA 
Stigma against OUD and its treatment methods affects many of the factors that ultimately 
determine behavior in both rural and urban populations. One factor that can contribute to stigma 
is the perceived norms an individual has towards drugs and OUD. Perceived norms can be both 
detrimental and helpful when planning interventions to decrease overdose and OUD. The 
perceived norm that drugs are bad and harmful to a person’s body can prevent people from 
originally misusing drugs. This could be a benefit of perceived norms towards OUD and 
prevention efforts. However, the perceived norm that people who use drugs are bad or worse 
people than those who do not misuse drugs can make recovery more difficult for a person. It can 
also make it more difficult when planning interventions in communities and overcoming the barrier 
of stigma against people with OUD. In order to account for the impact of perceived norms, 
researchers can anticipate both impacts and plan accordingly by designing messages to influence 
perceived social norms to help reduce stigmatization.  
When considering strategies and interventions to overcome stigma to enhance access to 
care for OUD, researchers and practitioners should consider the affect that stigma has at both 
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personal and community levels on the desired outcome of the intervention. Stigma against MAT 
has contributed to low levels of access in rural areas. The stigmatization of people with SUD and 
OUD has created barriers to more OUD clinics opening their doors. Today, stigma has the ability 
to spread more quickly and cause more damage through technology, like social media.146  In order 
to overcome stigma when planning interventions and strategies to increase sustainable treatment 
for OUD, practitioners should consider conducting a stigma reduction training with participants 
that is facilitated by a person in recovery. These types of trainings have been shown to assist with 
overcoming the barrier of stigma against SUD.147   
5.2 STRATEGIES TO INCREASE ACCESS TO CARE  
Several different strategies can be used to increase access to OUD-related care in rural 
Pennsylvania. In order to address the lack of behavioral health providers in rural Pennsylvania, a 
collaborative care model can be adopted by providers. In general, a collaborative model of care 
combines behavioral with primary health care to better address the needs of the community. The 
collaborative care model or the integration of behavioral health into primary health care will allow 
individuals to gain access to essential services in rural areas that are plagued by barriers to care, 
such as transportation.148 Including all services in one place mitigates the transportation barrier, 
which can improve compliance to behavioral health treatment. Since behavioral health is also a 
need for effective MAT, this would also assist with increasing access for treatment for OUD.   
In rural Pennsylvania, a primary care provider could obtain their buprenorphine waiver and 
open a collaborative care clinic. A psychologist could join the office as well as a licensed clinical 
social worker. Therefore, counseling services, primary medical care, and OUD treatment could be 
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available in one place. This would decrease the potential barrier of transportation and increase 
access to treatment in rural areas. The integration of behavioral health also helps individuals 
coordinate their medical care. Mental health disorders are a common co-morbidity to SUD, so this 
can also increase the ability to receive the necessary counseling for both forms of disease.  
Telemedicine can be optimized in rural areas to assist with the low access to medical 
care.102 It can supplement current in-person care in the underserved regions of the Commonwealth 
by using technology to disseminate medical recommendations to patients as well as other 
providers.149 For example, a specialist located in a major city can meet with a patient while they 
are with their family medical doctor five hours away in a rural community. Telemedicine can assist 
in the diagnosis and treatment of OUD. Using telemedicine, specialists in addiction and OUD can 
provide patient screening, assessments, manage medications, provide counseling, and offer on-
demand treatment consultation services, such as questions related to side effects of withdrawal 
from opioids.150 Finally, increasing the use of telemedicine can also reduce health care costs. It 
can reduce the time and space necessary in a brick and mortar office space for providers as well as 
travel expenses for patients.151 A multitude of barriers can be overcome by sharing medical advice 
through the use of technology.  
5.3 MEDICAID POLICY CHANGE PROPOSAL  
The services provided under Medicaid and the levels of reimbursement that providers receive can 
be adapted in a number of ways to better treat OUD in rural and urban patient populations. First, 
Medicaid can increase the availability of telemedicine services for the management of OUD. This 
will increase access to services for OUD in rural populations. The increase in use of telemedicine 
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can also benefit the payers in each county of the Commonwealth by decreasing healthcare costs in 
both rural and urban populations.152  
Second, medical care can be provided in a comprehensive manner and be expanded to 
include therapies, like MAT with buprenorphine. Medicaid can also change policies to make it 
easier to integrate behavioral health by eliminating billing restrictions that discourage integration 
efforts.153,154 This can provide more opportunities for rural citizens to receive primary medical care 
and behavioral health care in the same place, by decreasing barriers like transportation.  
Third, Medicaid can ease the administrative burden it puts on MAT providers by 
eliminating prior-authorizations for buprenorphine and naltrexone. This can increase the number 
of buprenorphine providers in both rural and urban counties by allowing them to treat OUD like 
other illnesses.155 Fourth, policy should be created that increases funding and access to 
detoxification providers throughout the Commonwealth. The lack of detoxification providers 
ultimately increases the cost of healthcare for all payers because of the increase in emergency room 
visits and hospital stays for detoxification-related services.156,157 Finally, Medicaid can incentivize 
and increase reimbursement for MAT and proper management of OUD. Increased funding for 
services that specifically address the needs of rural populations, such as funding for recovery 
support services, will also create a better opportunity for successful recovery from OUD in rural 
communities.  
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6.0  CONCLUSION   
One hundred-forty five Americans die each day from an opioid-related drug overdose. In 2016, 
4,642 drug overdose deaths occurred in Pennsylvania. The opioid epidemic affects all groups of 
people, and the death toll continues to take more lives each year. The outcome of OUD in an 
individual can be affected by a number of upstream and downstream factors. This paper used the 
SEM to organize those factors into multiple levels to show their effect on both rural and urban 
populations. A literature review was conducted to determine variations in rural and urban 
populations and the results were thematically analyzed and organized into the individual, 
interpersonal, community, organizational, and policy levels of the SEM. The SAMHSA provider 
search tool was also used to determine the number of providers in each Pennsylvania County and 
then corresponding provider rates by each counties total population.   
Following analysis, several factors were shown to impact rural communities more strongly 
than urban communities. The occupation an individual possesses, social networks, recovery 
support services, and access to healthcare and treatment options for OUD were all found to impact 
rural communities more strongly than urban. Rates of detoxification and MAT were found to be 
lower in rural than urban counties. Individual risk factors and perceived norms as well as family, 
the influence of one’s peers, stigma, SES, and policy were all found to affect both rural and urban 
populations. Rates of SUD and mental health treatment providers were found to be similar across 
rural and urban counties. All of these factors intermix to impact outcomes like OUD in various 
ways in the rural and urban populations in Pennsylvania.  
Several strategies can be used to overcome stigma against OUD and increase access to 
buprenorphine, detoxification, and drug and alcohol and mental health providers. The integration 
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and coordination of behavioral health into primary care can increase access to treatment to 
common mental health comorbidities with OUD. Telemedicine can be optimized to increase access 
to specialty providers, access to SUD screening, medication management, and counseling. In order 
to make these both possible, Medicaid policy can be adapted to increase the number of services 
that are reimbursed as well as increase the incentives for performing MAT. Medicaid can also ease 
the administrative burden it puts on providers by eliminating prior authorizations for providers to 
prescribe buprenorphine and streamlining behavioral health integration into primary medical care. 
Importantly, these methods also have the potential to decrease downstream healthcare costs due to 
fewer emergency room and hospital visits for OUD-related care.  
There are several limitations to this thesis. The search strategy eliminated the use of 
Diagnostic and Statistical Manual of Mental Disorders-IV classifications for mental disorders. For 
example, substance abuse and substance dependence were not searched for; therefore, this strategy 
may have eliminated some sources of information. A second limitation of the methodology used 
in this thesis was the use of the SAMHSA locator search tool to determine the number of providers 
in each county. Providers may not have registered with SAMHSA, resulting in an inaccurate count 
of providers when extracting information for the figures from the database. The SAMHSA search 
tool also did not allow for the number of patients treated by each provider to be calculated. 
Methadone providers were also not counted during treatment provider analysis. Therefore, access 
to one of the treatment providers for OUD was not analyzed in this paper.  
A third limitation was the way rural was defined in this thesis. Different entities define 
rural and urban populations in diverse ways, which creates issues when researching rural and urban 
communities. The Center for Rural Pennsylvania definition was used in this thesis because it was 
the definition used in the 2016 Drug Enforcement Agency Report. The data on overdose deaths 
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and death rates were extracted from the same 2016 report. The Center for Rural Pennsylvania’s 
definition was also used because The Center for Rural Pennsylvania is a legislative agency of the 
Pennsylvania General Assembly. This legislative agency uses their definition when developing 
new policy and adapting existing policies across the Commonwealth of Pennsylvania.  
There is no simple solution to solving the opioid epidemic and variations in access to care 
throughout the nation. It will require a combination of approaches that work together to overcome 
the multitude of barriers present at individual, environmental, and policy levels. This can be 
accomplished by working to integrate new methods of patient care, acknowledging and 
overcoming stigma, and adapting Medicaid policy to more accurately account for the current 
landscape of healthcare in the United States. The continued rise of synthetic opioids throughout 
both rural and urban communities is making it even more difficult to manage OUD and overdose 
in this county. Coordination and flexibility should be optimized to increase access and account for 
the various differences in rural and urban populations. Future policy in healthcare should account 
for the differences between rural and urban populations so that the needs of both are met 
accordingly, and a uniform decrease in overdose deaths can be seen across Pennsylvania and the 
United States.  
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APPENDIX: PRISMA FLOW DIAGRAM OF SEARCH RESULTS 
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